Navigation Links
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
Date:4/15/2008

ause Alzheimer's disease," said Dr. O'Nuallain. "These initial findings could be promising in Alzheimer's disease research using naturally occurring antibodies."

The oral presentation at AAN, entitled "Affinity Isolation and Characterization of Abeta Conformer-Reactive Antibodies Contained in Human Immune Globulin (IVIG)," showed that GAMMAGARD contains naturally occurring antibodies that directly bind to different forms of beta-amyloid protein, including oligomers and fibrils.

"Observations from this study provide insight into how GAMMAGARD LIQUID may be of potential clinical benefit for Alzheimer's patients," said Dave Morgan, director of Neuroscience Research, University of South Florida. "This study suggests that GAMMAGARD LIQUID may target the primary pathway involved in Alzheimer's disease and justifies additional studies to evaluate whether GAMMAGARD LIQUID can effectively reverse the effects of Alzheimer's disease."

According to the Alzheimer's Association, an estimated 5.2 million Americans have Alzheimer's disease, including one out of eight people age 65 and older, and the number of new cases per year is expected to grow to 454,000 by 2010. No cure currently exists that can halt or delay the brain deterioration associated with Alzheimer's disease, but new research shows encouraging results. The study's findings showed how the mechanism of action of GAMMAGARD may work on multiple forms of the beta-amyloid peptide to protect the human brain from dementia and may facilitate the development of treatment for patients with Alzheimer's disease.

Additional GAMMAGARD Trials in Alzheimer's Disease

At the AAN meeting, other studies will be presented on the use of GAMMAGARD in Alzheimer's disease. One oral presentation scheduled for April 17 - "A Double-Blind, Placebo-Controlled, Phase II Clinical Trial of Intravenous Immunoglobulin (IVIG) for Treatment of Alzheimer's Disease" - will discuss the evaluation of the efficacy, tolerabil
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... The Appignani Bioethics Center, a project of the American ... National Press Club to examine controversial emerging technologies in ... by Jonathan Moreno and Andrew Light, both of the ... ethical and political angles. , A video of ...
... Realty Trust, Inc. (NYSE: BMR ) announced today that the ... on its unsecured line of credit by $65 million to an ... of the facility. The weighted-average effective interest rate of the ... The maturity date remains August 1, 2011, which may be extended ...
... SAN DIEGO, Nov. 9 NexBio, Inc. announced the ... College of Allergy, Asthma, and Immunology in Miami, Florida. ... Decreases Airway Resistance and Has Potent Anti-inflammatory Effects in ... is an investigational broad spectrum host-targeting drug candidate being ...
Cached Biology Technology:Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 3BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 3NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
(Date:8/29/2014)... ANTONIO (Aug. 29, 2014) Scientists at the Barshop ... School of Medicine at the UT Health Science Center ... in the tissues of the longest-lived rodent, the naked ... in the cells of naked mole rats protects and ... for damaged and obsolete proteins. , The factor also ...
(Date:8/29/2014)... Until recently, little has been known about what ... international team of scientists, one of whom is a ... by showing that genes controlling the development of the ... rabbit domestication., The study was published Aug. 28 in ... questions. It is online at http://www.sciencemag.org/ ., The ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... Exposure to light and possibly photosynthesis itself could be helping ... impervious to washing, according to research published in the October ... Salmonella enterica is a common cause of ... million human cases per year in the United States. ...
... emissions trading has put a price on something that used ... , Allocating free allowances creates problematic expectations among companies; "If ... number of emission allowances tomorrow." This runs completely counter to ... Wrke, at the University of Gothenburg, Sweden. Markus Wrke ...
... Physical Laboratory (NPL), the UK,s National Measurement Institute, is ... of organic electronics. The market for organic, or plastic, ... 2015 (IDTechEx), and NPL is seeking to ensure the ... commercial success in this emerging area. The technology ...
Cached Biology News:Light, photosynthesis help bacteria invade fresh produce 2The EU must allocate fewer emission allowances and stop making free allocations 2The EU must allocate fewer emission allowances and stop making free allocations 3NPL supports growing organic electronics industry 2
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
... Beta-Agarase is useful in recovering DNA ... Beta-Agarase digests the agarose into oligo- ... Heat Inactivation: 65C, 15 min Molecular ... Purity: Tested for contaminating endonucleases, exonucleases ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
iEMS Thermal Microplate Holder...
Biology Products: